Goldman Sachs Reinstates Kodiak Sciences with Neutral Rating Amid Sector Resilience

Goldman Sachs has reinstated coverage on Kodiak Sciences Inc. (NASDAQ: KOD) and assigned it a Neutral rating, alongside a price target of $36.

The decision comes as the biotechnology sector shows resilience despite macroeconomic headwinds.

Kodiak Sciences is currently unprofitable and cash-flow-negative, with a high market cap of $1.98 billion and a P/S ratio that reflects high expectations for future growth.

Despite its weak profitability, the company has a moderate financial strength, supported by a healthy current ratio of 2.49 and a cash ratio of 2.39.

The GF Score™ indicates modest overall fundamental health with particular weaknesses in profitability, but moderate momentum.